Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis

Jocelyn Thomas; Mohammed Mujaab Kamso; Samuel Whittle; George A. Wells; Shannon Kelly; Jordi Pardo Pardo; Peter Tugwell; Renea V Johnston; Vanessa Glennon; Maede Ejaredar; Megan Thomas; Chloe Lee; Jesse Elliott; A M Mokbel; Jodie Avery; Liesl Grobler; Sheila Cyril; Rob Deardon; Elie A. Akl; Lara Maxwell; Rachelle Buchbinder; Glen Hazlewood; Supported by the Cochrane Musculoskeletal Health and Pain Thematic Group

doi:10.1002/14651858.cd013562.pub2

Key Points

To compare benefits and harms of DMARDs following inadequate response to biologic or targeted synthetic DMARDs in rheumatoid arthritis.
Conducted a systematic review and network meta-analysis.
Included randomized controlled trials of adults with rheumatoid arthritis and inadequate response to biologic therapy.
Searched multiple databases and applied risk of bias assessments using Cochrane's RoB 1 tool.
Found high-certainty evidence that several DMARDs improved disease activity significantly compared to placebo.
Moderate-certainty evidence indicated potential harms associated with certain therapies, with inconclusive comparisons among interventions.
Overall effectiveness varied, supporting tailored treatment based on individual patient characteristics.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Systematic review compares DMARD outcomes in adults with rheumatoid arthritis after biologic therapy failure, suggesting tailored treatment decisions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thomas et al. (2026) studied this question.

synapsesocial.com/papers/6a57231a88b21df87547fe02 https://doi.org/10.1002/14651858.cd013562.pub2

View Full Paper

Ask AI

Bookmark

Share

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta-analysis

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading